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The Simon two-stage minimax design is a popular statistical design used in Phase II clinical trials. The analysis of the data arising
from the design typically involves the use of frequentist statistics. This paper presents an alternative, Bayesian, approach to the
design and analysis of Phase II clinical trials. In particular, we consider how a Bayesian approach could have affected the design,
analysis and interpretation of two parallel Phase II trials of the National Cancer Centre Singapore, on the activity of
gemcitabine in chemotherapy-naı ¨ve and in previously treated patients with metastatic nasopharyngeal carcinoma. We begin by
explaining the Bayesian methodology and contrasting it with the frequentist approach. We then carry out a Bayesian analysis
of the trial results. The conclusions drawn using the Bayesian approach were in general agreement with those obtained from
the frequentist analysis. However they had the advantage of allowing for different and potentially more useful interpretations
to be made regarding the trial results, as well as for the incorporation of external sources of information. In particular, using a
Bayesian trial design, we were able to take into account the results of the parallel trial results when deciding whether to
continue each trial beyond the interim stage.
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There are many stages in the process of developing an anti-tumour
drug and one key stage is the assessment of efﬁcacy in Phase II
trials. This is usually demonstrated by using tumour response as
the indicator. To this end many thousands of Phase II trials have
been conducted. In particular during the ongoing development
and assessment of gemcitabine (a ﬂuoride–substituted anti-meta-
bolite) many such trials have already been published (see for
example Lund et al, 1994), including those that will be the main
focus of this paper (Foo et al, 2002), and many more are in
progress. In general each trial is addressing essentially the same
type of question (tumour response) but in a wide variety of
disease, patient types and in combination therapies.
The basic designs (in the statistical sense) vary from the infor-
mal with no justiﬁcation of trial size given (see for example,
Giralt et al, 1997), to the popular two stage Gehan (1961) design
(see for example, Scheithauer et al, 1999) and the more recent
designs as, for example, proposed by Simon (1989). The corre-
sponding analysis of the data arising from these designs is
detailed below but is essentially straightforward.
In contrast to the above so-called frequentist designs, several
Bayesian designs have been proposed for Phase II trials (see for
example, Thall and Simon, 1994; Heitjan, 1997; Stallard, 1998).
In this paper, we give a brief overview of the Bayesian approach
and show how it could have affected the interpretation of a report
of two parallel Phase II trials, conducted at the National Cancer
Centre Singapore, on the activity of gemcitabine in patients with
metastatic nasopharyngeal carcinoma (NPC).
MATERIALS AND METHODS
Phase II trials of gemcitabine
The trials investigated the activity of gemcitabine in chemotherapy-
naı ¨ve as well as in previously treated patients with metastatic NPC
and were run in parallel, with a common protocol. Patients with
ECOG performance status 42, adequate renal, hepatic, and bone
marrow function, and radiologically measurable NPC, were eligible.
All patients were given a maximum of six cycles of gemcitabine at a
dose of 1250 mg m
72 on days 1 and 8 of a 21-day cycle.
The primary objective in each of these trials was to evaluate the
tumour response. ‘Response’ was deﬁned as the sum of both partial
and complete responses. Patients who were not evaluable were
regarded as failures (non-responders) for the purpose of efﬁcacy
determination. Patients who were chemotherapy-naı ¨ve and those
who had prior chemotherapy were registered, by means of a tele-
phone call through the Clinical Trials and Epidemiology Research
Unit, National Medical Research Council, Singapore.
Full details of the background and results from the two trials are
given in Foo et al (2002).
Statistical methods
Frequentist design The sample size was estimated separately for
each trial assuming a one-sided test size of 5% and a power of
80%. As part of the Simon (1989) two-stage minimax design, it
was necessary to specify, for each of the patient groups, a ‘desired
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rate’ (R0). Chemotherapy-naı ¨ve patients were enrolled in the ﬁrst
trial (Trial C), which assumed a desired overall response rate of
30% (R1=0.30), and a no further interest response rate of 10%
(R0=0.10). Using the Simon two-stage minimax design, 15 patients
were to be recruited into Stage 1 requiring at least two responses
before proceeding to the recruitment of an additional 10 patients
in Stage 2. Efﬁcacy was to be claimed if six or more responses were
observed from the total of 25 patients.
Similarly patients who had been previously treated with
chemotherapy were enrolled in the second trial (Trial P), which
assumed an overall response of interest to be 20% (R1=0.20),
and no further interest in gemcitabine if the response was as low
as 5% (R0=0.05). The Simon minimax two-stage design indicated
the recruitment of 13 patients in Stage 1 requiring at least one
response before proceeding to Stage 2 with a further recruitment
of 14 patients. Efﬁcacy was to be claimed if four or more responses
were observed from the total of 27 patients.
Frequentist analysis The (frequentist) analysis of response rate
from the Phase II trial is straightforward in that the number of
responses observed, r, is divided by the number of patients
recruited, N. Thus the observed response rate is ^    r
N which is
an estimate of the true population response rate y. The distribution
of y is Binomial, which has a likelihood proportional to
likxj/ x1 ÿ 
Nÿx 1
where the x’s are the possible number of responses in the Phase II
trial which can take any integer value from 0 to N.
Although by no means always calculated, the corresponding 95%
conﬁdence interval (CI) for y is often estimated by ^  
71.966s.e.(^  )t o^  +1.966s.e.(^  ). However, this expression is
applicable only for relatively large N which is not usually the case
for Phase II trials. In these circumstances, Newcombe and Altman
(2000) describe better methods. They also point out that even if no
responses are observed, that is r=0, there is still indeed a 95% CI
for y which is from 0 to 4
N4.
Bayesian design and analysis The foundation of this approach
is Bayes’ theorem, which can be expressed as
postjx/likxj prior : 2
Here the lik(x|y) of equation (1) is multiplied by the prior distri-
bution, prior (y), to obtain the posterior distribution, post (y|x).
The prior (y) summarises what we know about y before the trial
commences and as previously, lik(x|y) describes the data to be
collected from the trial itself. Finally post (y|x) summarises all we
know about y once the trial is completed.
The prior distribution is assumed to be of the form
prior / aÿ11 ÿ 
bÿ1: 3
This is a Beta distribution with parameters a and b, which can take
any positive real value. When a and b are integers, such a distribu-
tion corresponds to a prior belief equivalent to having observed a
responses out of a hypothetical T=(a+b) patients. This is then
similar to the situation modelled by the binomial distribution
(see equation (1)), in which we have x as the number of responses
from N patients.
Using equations (1) and (3) in equation (2) results in a poster-
ior distribution of the form
postjx/axÿ11 ÿ 
bNÿxÿ1: 4
Comparing this with equation (3), we see that this too is a Beta
distribution, but of the form Beta (a+x, b+N7x).
As mentioned previously, the posterior distribution represents our
overall belief at the close of the trial about the distribution of the
population parameter, y. Once we have obtained the posterior distri-
bution, we can calculate the exact probabilities of y being in any
region of interest or obtain summary statistics such as its mean value.
Priors The prior distribution summarises the information on y
before the trial commences. We make use of four such types of
distributions – clinical, reference, sceptical and enthusiastic. The
general way in which each of these are derived is as follows.
The shape of a Beta distribution is dependent on the values of
the parameters a and b, and each of the priors will have particular
values associated with them. However, eliciting values for a and b
is typically not an easy process. Instead, it is often much easier to
obtain values for the mean (M) and variance (V) of the corre-
sponding prior distribution. Once obtained, these values can then
be used to obtain a and b by solving the simultaneous equations
M 
a
a  b
; V 
ab
a  b
2a  b  1
; 5
which give
a 
MM1 ÿ MÿV
V
;b 
1 ÿ MM1 ÿ MÿV
V
6
Clinical prior This represents the combined prior belief of
informed experts. This will include the subjective prior opinions
of the trial investigators and/or other experts, as well as the results
of previous similar studies.
Before the start of the trials, no plans were made to carry out a
Bayesian analysis of the results. As such, no prior opinion was
elicited from the investigators. There were also no published
reports on the effect of gemcitabine on tumour response in meta-
static NPC patients from which we could derive a clinical prior.
However, the investigators were asked for their opinions on the
values of R0 and R1. For our clinical prior, we then assumed that
the investigators’ prior belief was such that there was equal prob-
ability (here 1
3)o fy being below R0, between R0 and R1, and
above R1. Using the pbeta and qbeta functions in the S-Plus statis-
tics software (S-Plus 2000 Professional Release 1, MathSoft Inc),
appropriate values for a and b were then calculated to deﬁne such
a Beta distribution.
In mathematical terms, this was done by ﬁnding the a and b
values that satisfy the integral equation:
Z b
a

ÿa  b
ÿaÿb
 aÿ11 ÿ 
bÿ1

d 
1
3
for (a, b) taking the successive values (0, R0), (R0, R1) and (R1, 1).
Reference prior A reference or non-informative prior corre-
sponds to the situation when no or very little prior information
is available. In practice, this will not often be the case, since the
trial investigators are likely to have at least some opinion on the
effect of the treatment. Nevertheless, reference priors are useful
particularly when we want to focus on just the trial data alone.
In this respect, using a reference prior in a Bayesian analysis is
similar to carrying out a frequentist analysis, although the manner
in which the data is analysed and reported is still very different.
We chose our reference prior distribution to be a uniform (that
is ‘ﬂat’) distribution over the entire real line. This corresponds to a
state of complete uncertainty.
Sceptical prior A sceptical prior represents the beliefs of indivi-
duals who are reluctant to accept that high response rates are
possible. Such a prior would be useful for guarding against the
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expectations.
We deﬁned our sceptical prior to have a Beta distribution with a
mean ﬁxed to be R0 while the probability of exceeding R1 is set to
0.05, where the small probability of 0.05 is arbitrarily chosen.
Enthusiastic prior An enthusiastic prior is the opposite of a
sceptical prior and represents the beliefs of individuals who already
accept that the new treatment being tested is promising enough to
warrant testing in a Phase III trial. Such a prior would be useful,
for example, in the situation where we wish to ensure that poten-
tially good drugs are not rejected on the basis of a handful of ‘not
good enough’ results.
We chose our enthusiastic prior to have a Beta distribution with
a mean ﬁxed to be R1 while the probability of being below R0 is set
to 0.05.
Combining the two trials
From a frequentist viewpoint the two trials considered, although
conducted in parallel, are regarded as entirely independent of each
other. Thus, the decision to proceed from Stage 1 to Stage 2 in
each trial was made without reference to the other. However, there
is a detailed record of when the information on response became
available for each patient, and so we can illustrate (at least in part)
how using Bayesian methods, they may have been considered
jointly. To do this we assume, that before proceeding into Stage
2 of either trial, the response information is reviewed so that
instead of automatically implementing the Simon rule, the current
posterior distribution of y for the respective trial is calculated
(taking into account the information available from both trials).
If this suggests that y has a relatively high probability (say,
50.25) of exceeding R1 then Stage 2 is implemented else the parti-
cular trial stops at the completion of Stage 1. We refer to 0.25 as
the threshold probability and denote it by l.
The above assumes that data from both patient groups are
exchangeable in the sense that they contribute an equal weight of
information to the response. This is not likely to be valid as it
implies that only one Phase II trial would be necessary in patients
with NPC and no particular note taken of their prior treatment
history. Consequently, a weighting is required whereby the infor-
mation (as summarised by the posterior distribution) from one
group is adjusted downwards if it is being used to modify the prior
of the other. The assumption here is that (say) a ‘satisfactory’
response rate in one group may indicate that a ‘satisfactory’
response rate is likely to be observed in the other but the rates
in each group may not be the same.
This down weighting can be done by increasing the variance of
the posterior distribution but retaining the same mean value. This
is accomplished by replacing V in equation (6) by kV, where k41.
This reduces the values of both a and b and is analogous to redu-
cing the number of patients on which the mean and variance are
based.
RESULTS
Trial outcome and frequentist analysis
A total of 52 patients (25 chemotherapy-naı ¨ve, 27 previously
treated with prior chemotherapy) were enrolled between January
and November 1999.
Of the 15 chemotherapy-naı ¨ve patients recruited in Stage 1 of
Trial C, three achieved a response. The recruitment of a further
10 patients as speciﬁed in Simon’s design was thus initiated in
Stage 2. Of these, four achieved a response. The overall response
to gemcitabine among the 25 patients of Trial C was thus 7
25 or
28% (95% CI: 14 to 48%). This just exceeded the 24% threshold
needed to claim efﬁcacy as speciﬁed in the design.
Of the 13 previously treated patients recruited in Stage 1 of Trial
P, seven achieved a response. This led to a subsequent recruitment
of 14 more patients in Stage 2, with six additional responses being
observed in this group. The overall response to gemcitabine among
the 27 patients of Trial P was thus 13
27 or 48% (95% CI: 31 to 66%),
which well exceeded the 15% threshold needed to claim efﬁcacy.
Bayesian analysis – chemotherapy-naı ¨ve group (C)
Analysis The prior and Stage 2 posterior distributions are given
in Figure 1. The results are summarised in Table 1. Using the
clinical prior distribution of Beta (0.7, 2.1), the posterior distribu-
tion for the chemotherapy-naı ¨ve group after Stage 1 is now Beta
(0.7+3, 2.1+12) or Beta (3.7, 14.1). This is shown, together with
the clinical prior, in Figure 2. The data from Stage 1 has updated
the prior belief by ‘shifting’ the distribution towards the right, so
that most of the distribution now falls within the interval R0=0.1
to R1=0.3. The associated probability has increased from 0.321 to
0.723 (Table 1). This represents the posterior belief after having
taken into account the results of Stage 1. This updated belief is
intuitively reasonable since the 20% response (three responses
out of 15) from Stage 1 suggests that yc is likely to fall between
the predeﬁned R0 and R1.
The 40% response from Stage 2 (four responses from the subse-
quent 10 patients) leads to a (further updated) posterior
distribution Beta (3.7+4, 14.1+6) or Beta (7.7, 20.1). The posterior
distribution after Stage 2 as shown in Figure 2 again falls mainly in
the interval R0 to R1. The distribution is sharper and narrower than
that obtained for Stage 1. This reﬂects the increased certainty asso-
ciated with the posterior beliefs after Stage 2, due to a larger total
amount of data now being available.
We note that although the 40% response in Stage 2 might have
suggested that the main bulk of the updated posterior would fall in
the interval corresponding to yc40.3, this is not the case and the
bulk remains within 0.15yc40.3. This is because the sample size
in Stage 1 is larger than that in Stage 2. Hence, the results from
Stage 1 have a larger inﬂuence on the ﬁnal posterior belief than
the results from Stage 2.
Thus, under the clinical prior, the ﬁnal (after Stage 2) posterior
distribution suggests that there is a 62% chance (Table 1) of the
true response proportion being between R0=0.1 and R1=0.3, while
the probability that it is greater than R1 is about 37%. There is only
a 1% chance that it will be less than R0.
Interpretation We recall that R0 corresponds to the ‘no further
interest response rate’ and R1 to the ‘desired overall response rate’.
In which case, the above can be interpreted: that while there is a
very strong case for carrying out further investigations of the treat-
ment, the results are not quite as promising as was desired before
the start of the trial.
Using the reference prior, we obtain results that are quite similar to
those obtained when we used the clinical prior (see Figure 3A and
Table 1), with for example the Stage 2 probability of yc exceeding
R1 being 0.389 as opposed to 0.372. The reason for this is that the
clinical prior we used is also quite ‘non-informative’, in the sense that
it attaches equal probability to yc being in each of the three regions.
On the other hand, as might be expected, the sceptical prior
suggestsadistributionforycwhichis‘totheleft’ofthatobtainedusing
the clinical prior (Figure 3B). Correspondingly, the Stage 2 value of
Prob(yc4R1) is also less than 0.372 (Table 1, row 9). For the enthu-
siastic prior, the distribution is ‘to the right’ of that obtained with
the clinical prior (Figure 3C) with the Stage 2 value of Prob(yc4R1)
being somewhat greater than 0.372 at 0.406 (Table 1, row 12).
Bayesian analysis – previously treated group (P)
Analysis The prior and Stage 2 posterior distributions are given
in Figure 4. The results are summarised in Table 2 where all the
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(6), 843–850corresponding Stage 1 and 2 posterior distributions strongly
suggest that the true response proportion for these patients (yp)
exceeds the R1=0.2 threshold. This is due to the relatively high
number of responses in both Stage 1 (seven out of 13) as well as
Stage 2 (six out of 14) observed. Even with the sceptical prior,
the Stage 1 and 2 posteriors still suggest high probabilities, 0.940
and 0.993 respectively, of yp exceeding R1.
Interpretation The evidence from the trial data, of yp being
greater than 0.2, is so strong that it is enough to completely change
the belief of an individual who, before the start of the trial, felt that
there was only a 5% chance of this being possible (as represented
by the sceptical prior). In fact, the sceptic’s prior belief has been
modiﬁed by the data to such an extent that he now believes that
there is a 99% chance that yp exceeds 0.2 (Table 2, row 9).
Combining the results of both trials The information with
respect to the four stages became available in the order Stage P1,
Stage C1, Stage P2 and ﬁnally Stage C2. Thus, the ﬁrst decision
to be made is whether to continue to Stage P2 – this will be made
without reference to data from Trial C. Using the clinical prior and
the data from Stage P1, the resulting posterior distribution with
a=7.6, b=9.0 indicates very strongly that Stage P2 should be
initiated since the probability that yp is greater than R1=0.2 is
0.990 (see Table 2).
The second decision is whether to continue to Stage C2 –
however, this will be made in the light of the clinical prior for Trial
C together with the Stage C1 and Stage P1 results. Thus the clinical
prior for Trial C, will be updated by the data of Stage C1 and then
by the (down-weighted) posterior from Stage P1. The ﬁrst poster-
ior distribution with a=3.7, b=14.1 (from the clinical prior and the
data only) indicates only rather weakly that Stage C2 should be
initiated since the probability that yc is greater than the corre-
sponding R1=0.3 is only 0.164 (see Table 1). However, this is
now combined with the down weighted posterior following Stage
P1. For illustrative purposes, we choose k=4. This results in using
a posterior with a=1.6 and b=1.8 which is combined with a=3.7
and b=14.1 to obtain for the second and ﬁnal posterior distribu-
tion a=1.6+3.7=5.3 and b=1.8+14.1=15.9. From this distribution,
the probability that yc is greater than R1=0.3 is now 0.278. This
is (just) above the threshold value of 0.25 (see Discussion) and
indicates that Stage C2 should be initiated.
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Figure 1 Prior and Stage 2 posterior distributions for the chemotherapy-naı ¨ve group.
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The process of decision making should involve the consideration of
evidence from all available sources of information. For example, a
physician who wants to make a diagnosis of a patient’s condition is
unlikely to base the conclusion solely on what is observed during a
clinical examination. Instead, account will be taken of the patient’s
past medical history, along with appropriate blood or other clinical
test results. In more complex cases, the physician may also discuss
the case with others or consult the medical literature. By analogy,
we should not take the results obtained from the clinical trial
alone, but place them in the context of other pertinent informa-
tion.
Bayesian methods attempt to formalise this decision making
process. In the context of a clinical trial, it provides a way whereby
the trial data is combined with data from pilot studies, results of
similar trials, subjective clinical opinion and other sources of infor-
mation. Any decisions or conclusions made will then have been
based on all available information.
In the context of the Phase II trials of gemcitabine in patients
with metastatic NPC, the frequentist analysis estimates the true
rates yc (for chemotherapy-naı ¨ve) and yp (for previously treated)
as 28% and 48% respectively. The uncertainty associated with these
estimates is quantiﬁed by the 95% CI. However, this CI does not,
as is commonly understood, refer to an interval which contains y
(either yc or yp) with a 95% probability. Instead, it refers to the
interval that, should the trial be repeated again and again, will
contain y exactly 95% of the time. Since we are unlikely ever to
repeat the trial again, this property is somewhat non-intuitive in
nature. In addition, the frequentist estimate of the response rate
and corresponding 95% CI, take no note of any external informa-
tion.
In a Bayesian framework, y is not treated as a ﬁxed value, but is
regarded as a variable with a probability distribution to be deter-
mined. This then allows the calculation of the probability that y
lies in a given interval. This enables simpler and more direct inter-
pretations to be made regarding the results of the trial. For
example, in Table 1, we give the posterior probability values of
yc being less than R0, being between R0 and R1 and being greater
than R1. In fact, we can calculate the probability values of yc being
in any interval of interest, not just at those deﬁned by R0 and R1.
Thus, suppose we were interested in obtaining the ﬁnal posterior
probability, having started with the clinical prior, that yc exceeded
0.4. From Figure 2, this is the area under the Stage 2 posterior
curve which exceeds yc=0.4. This turns out to be 0.080, that is
there is a probability of 8% that the true response proportion
exceeds 0.4 or 40%.
The above are some of the possible advantages of using a Baye-
sian approach. However, there are also some difﬁculties. Foremost
among these, is the ‘subjective’ nature of Bayesian approaches. Also
criticised, is the perceived difﬁculty and relatively longer computa-
tional time required to carry out Bayesian computations as
opposed to frequentist ones. Many articles have been written
debating the pros and cons of Bayesian approaches and some of
these are discussed by Berry and Stangl (1996) and Senn (2000).
Based on the response rates and their associated CIs, Foo et al
(2002) concluded that gemcitabine has moderately high single-
agent activity in NPC of the undifferentiated type whether as a
ﬁrst-line or as a salvage treatment. They comment that, while it
appears that those who had prior treatment seemed to respond
better to gemcitabine, this can possibly be explained by patient
selection. Those who had prior chemotherapy had better perfor-
mance status and lower disease bulk as evidenced by the fewer
sites of distant metastases at accrual.
Formulated in Bayesian terms, the conclusions would be rather
similar except perhaps that one would quote the respective prob-
abilities that y5R1 of lC=0.372 and lp=0.999 using the clinical
priors. However, for the chemotherapy naı ¨ve group sceptical prior
distribution the probability that yC50.3 is relatively small as
lC=0.156. Thus, there remains some concern with respect to efﬁ-
cacy and hence further study. In contrast, for the previously
treated group, there is a large probability that yP50.2, here
lp=0.993. Gemcitabine is clearly recommended for further study
in this situation.
In the particular circumstance of two similar trials running in
parallel, we have illustrated how Bayesian methods could be used.
In this case to allow the Stage 1 results from one trial to inﬂuence
the decision to proceed to Stage 2 for the other. For didactic
reasons, we have utilised the clinical prior only in this. Essentially,
the (down-weighted) posterior distribution following the results of
Stage 1 in one trial is combined with the posterior distribution
calculated at the end of Stage 1 in the second trial. This combined
posterior distribution is then used to calculate the probability that
the true proportion of response is greater than a predeﬁned thresh-
old. In this example, we have set the down-weighting factor k=4
and the threshold probability l=1
4=0.25.
The latter was set at 0.25 deliberately to (just) allow (under this
Bayesian monitoring) Stage C2 to be implemented. The calculated
probability was 0.278 whereas without the down-weighted poster-
ior following P1, it was 0.164 (Table 1, row 2). Had the
enthusiastic prior been utilised the probability of 0.229 would still
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Table 1 Probability values of the regions of interest for the chemo-
therapy-naı ¨ve group
Probability (R0=0.1 R1=0.3)
Type of prior yc4R0 R05yc4R1 yc4R1
Clinical Prior 0.336 0.321 0.343
(a=0.7, b=2.1)
Stage 1 posterior 0.113 0.723 0.164
Stage 2 posterior 0.006 0.623 0.372
Reference Prior – – –
(a=0, b=0)
Stage 1 posterior 0.158 0.681 0.161
Stage 2 posterior 0.007 0.604 0.389
Sceptical Prior 0.613 0.347 0.040
(a=1, b=9)
Stage 1 posterior 0.214 0.743 0.042
Stage 2 posterior 0.017 0.827 0.156
Enthusiastic Prior 0.053 0.484 0.463
(a=3, b=7)
Stage 1 posterior 0.028 0.744 0.229
Stage 2 posterior 0.001 0.593 0.406
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Figure 2 Clinical prior, Stage 1 and Stage 2 posterior for the chemother-
apy-naı ¨ve group.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(6), 843–850be less than the threshold l to continue to Stage C2. Clearly had
the threshold been set at l=0.3, for example, the trial would not
have continued.
The value of k=4 was chosen arbitrarily to reduce the standard
error of the (frequentist) estimate of y by 2. Fortuitously, this gave
a value just above the threshold we had set – enabling the trial to
continue in our theoretical setting. However, we have no direct
experience to suggest a ‘better’ value. But, just as clinical, sceptical
and enthusiastic priors may be obtained, then a range of values of
k may be sought and utilised. For example, we could have asked
the investigators, before the start of the trial, how relevant (on a
scale of 0 to 1) they felt information from the previously treated
group would be to the chemotherapy-naı ¨ve group, or vice-versa.
We could then take the average of all their opinions, and use the
inverse of this as our value of k. Alternatively, we could search
the literature for other studies (if necessary, involving other
tumour types or other treatment regimes) that give response rates
for chemotherapy-naı ¨ve and previously treated patients. These need
not come from the same study. We can then evaluate the ratio of
the two rates, and use the average of these as k.
It may be argued that our setting is rather unique, two parallel
trials using the same regimen and in the same disease. However, we
wouldclaim this is often the case. For example, in the recent literature
there are three related Phase II trials of single agent gemcitabine in
breast cancer – related in the sense of both overlapping authorship
and type of disease (metastatic and/or advanced) (Carmichael et al,
1995; Possinger et al, 1999; Schmid et al, 1999). However, the meth-
odology is equally applicable if the (down-weighted) prior had been
obtained from information external to the investigating team –
perhaps from the newly available literature.
Thus far, we have demonstrated how Bayesian methodology
could be usefully applied to the interpretation of Phase 2 trials
already designed using the two-stage Simon minimax design.
However, suppose instead we wished to prospectively use a Baye-
sian approach to design a Phase 2 clinical trial.
The two-stage Simon minimax design requires speciﬁcation of
four items, R0 and R1 as well as the Type I and II error rates.
The two stages (n1 + n2=N) are then chosen with the smallest N
possible to satisfy the speciﬁed error rates. Designs for a range of
values have been tabulated by Simon (1989) and others. In its
simplest form, where no external information is going to be avail-
able at the end of Stage 1, the Bayesian design requires speciﬁcation
of a prior distribution for y and a value for l.
Several authors have discussed the issue of specifying a prior
distribution for a Phase II trial. For example, Heitjan (1997)
propose standard forms for sceptical and enthusiastic priors, while
Thall and Simon (1994), Tan and Machin (2002) and others
propose forms for clinical and reference priors. All the proposed
methods involve eliciting appropriate summary values from the
investigators and deﬁning a prior distribution based on these. This
is similar to what we have done for our clinical prior, with the
clinician-elicited values of R0 and R1 being used to construct the
prior distribution. As far as eliciting a full prior distribution is
concerned, most of the work in this area has been in the context
of Phase III trials (see for example Parmar et al, 1994). However,
similar approaches could be used for Phase II trials.
As for specifying l, Tan and Machin (2002) recommend that
this should be chosen to give sample sizes which are practical for
Phase II trials. Choosing a larger value of l will increase the
‘power’ of the design, but at the cost of a larger sample size. There
is a need to trade-off wanting a high l value with keeping the
sample size reasonably small. This trade-off also happens in
frequentist designs, where the sample size is traded off against
the Type I and II errors.
C
l
i
n
i
c
a
l
P
 
(
t
h
e
t
a
)
0
2
4
6
8
0.0 0.2 0.4 0.6 0.8 1.0
Parameter value (theta)
Clinical Prior
Reference, Sceptical or Enthusiastic
P
 
(
t
h
e
t
a
)
0
2
4
6
8
P
 
(
t
h
e
t
a
)
0
2
4
6
8
0.0 0.2 0.4 0.6 0.8 1.0
Parameter value (theta)
0.0 0.2 0.4 0.6 0.8 1.0
Parameter value (theta)
Clinical & Reference A Clinical & Sceptical B
Clinical & Enthusiastic C
Figure 3 Stage 2 posterior distributions, corresponding to different priors, for the chemotherapy-naı ¨ve group.
Bayesian analysis of Phase II trials of gemcitabine in NPC
S-B Tan et al
848
British Journal of Cancer (2002) 86(6), 843–850 ã 2002 Cancer Research UKMore generally, values of R0 and R1 (from which a prior distri-
bution may be derived) as well as two threshold values, l0 and l1,
corresponding to the ‘interim’ and ‘ﬁnal’ thresholds would need to
be speciﬁed. The overall sample size would then be selected so as to
allow for an expected posterior probability of at least l1 that y
exceeds R1. The Stage 1 sample size would be selected so as to
allow for an expected posterior probability of at least l0, where
l05l1. Note that if we ﬁx l0=cl1 for some predeﬁned constant
c51, then only one threshold value needs to be speciﬁed.
However, these designs too would have to be tabulated or at
least specialised software made available for general use. Work
on tabulating the designs has begun (see Tan and Machin, 2002)
and we plan to implement these alongside the Simon minimax
design and other proposed Bayesian Phase 2 designs before making
a judgement on their practical usefulness. The additional possibility
of using external information at the decision point to continue to
Stage 2 can then be explored also.
In general, we believe that Bayesian methods have much to offer
the design, analysis and hence reporting of Phase II clinical trials.
These parallel their use in Phase III trials as has been advocated by
Spiegelhalter et al (1994) and others. In particular we have adopted
their concepts of sceptical and enthusiastic priors for our approach.
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Figure 4 Prior and Stage 2 posterior distributions for the previously treated group.
Table 2 Probability values of the regions of interest for the previously
treated group
Probability (R0=0.05 R1=0.2)
Type of prior yp4R0 R05yp4R1 yp4R1
Clinical Prior 0.332 0.348 0.320
(a=0.6, b=3.0)
Stage 1 posterior 0.000 0.010 0.990
Stage 2 posterior 0.000 0.001 0.999
Reference Prior – – –
(a=0, b=0)
Stage 1 posterior 0.000 0.004 0.996
Stage 2 posterior 0.000 0.001 0.999
Sceptical Prior 0.688 0.260 0.052
(a=0.4, b=7.6)
Stage 1 posterior 0.000 0.060 0.940
Stage 2 posterior 0.000 0.007 0.993
Enthusiastic Prior 0.050 0.508 0.442
(a=2.4, b=9.6)
Stage 1 posterior 0.000 0.024 0.976
Stage 2 posterior 0.000 0.003 0.997
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